Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib

Adam S Kittai, Ying Huang, Ashleigh Keiter, Kyle A Beckwith, Daniel Goldstein, Seema A Bhat, David A. Bond, John C. Byrd, Michael R Grever, Kerry A Rogers, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 3731.

https://doi.org/10.1182/blood-2021-144518

Published: 2021

Journal Articles

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Daniel Goldstein, MD, Kyle A. Beckwith, MDPhD, Cecelia Miller, PhD, Ying Huang, MS, MA, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, David A. Bond, MD, John C. Byrd, MD, Michael R. Grever, MD, Nyla A Heerema, PhD, Kerry A. Rogers, MD, Amy S. Ruppert, PhD, Jennifer A. Woyach, MD, Adam S. Kittai, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136714

Published: 2020

Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Deborah M Stephens, DO, Kyle A. Beckwith, PhD, Priscilla Do, BS, Carolyn Cheney, BS, Xiaokui Mo, PhD MAS, Karilyn Larkin, MD, Jeffrey Jones, MD MPH, Farrukh T. Awan, Laura Grosmaire, PhD, Randy Jones, PhD, Julie DiPaolo, PhD, Stacey Tannheimer, Karl-Heinz Heider, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2767.

https://doi.org/10.1182/blood.V128.22.2767.2767

Published: 2016

Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3238.

https://doi.org/10.1182/blood.V128.22.3238.3238

Published: 2016

Journal Articles

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Priscilla Do, BS, Kyle A. Beckwith, PhD, Larry Beaver, Brittany G. Griffin, Xiaokui Mo, PhD MAS, Jeffrey Jones, MD MPH, Erin K. Hertlein, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3221.

https://doi.org/10.1182/blood.V128.22.3221.3221

Published: 2016

Journal Articles

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Blood (2016) 127 (9): 1117–1127.

https://doi.org/10.1182/blood-2015-11-679134

Published: 2016

Includes: Supplemental data

Journal Articles

The Role of Tetraspanin CD37 in B-Cell Malignancy

Kyle A. Beckwith, BS, Erich I. Williams, BS, Mark D. Wright, PhD, Annemiek B. van Spriel, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2015) 126 (23): 1258.

https://doi.org/10.1182/blood.V126.23.1258.1258

Published: 2015

Journal Articles

Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients

Meixiao Long, MD PhD, Kyle A. Beckwith, BS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jennifer A. Woyach, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2015) 126 (23): 2940.

https://doi.org/10.1182/blood.V126.23.2940.2940

Published: 2015

Journal Articles

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

Zachary A. Hing, Rose Mantel, Kyle A. Beckwith, Daphne Guinn, Erich Williams, Lisa L. Smith, Katie Williams, Amy J. Johnson, Amy M. Lehman, John C. Byrd, Jennifer A. Woyach, Rosa Lapalombella

Blood (2015) 125 (20): 3128–3132.

https://doi.org/10.1182/blood-2015-01-621391

Published: 2015

Includes: Supplemental data

Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia

Deborah M Stephens, DO, Kyle A Beckwith, B.S., Carolyn Cheney, B.S, Xiaokui Mo, PhD MAS, Joseph M Flynn, D.O., MPH, Jeffrey A. Jones, MD, Kami J. Maddocks, MD, Karl-Heinz Heider, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2014) 124 (21): 4681.

https://doi.org/10.1182/blood.V124.21.4681.4681

Published: 2014

Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Blood (2013) 122 (15): 2539–2549.

https://doi.org/10.1182/blood-2013-06-507947

Published: 2013

Includes: Supplemental data

Journal Articles

A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics

Kyle A Beckwith, B.S., Frank W Frissora, M.S., Matthew R Stefanovski, B.S., Jutta Deckert, Ph.D., Carlo M Croce, M.D., Xiaokui Mo, PhD, David Jarjoura, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2012) 120 (21): 188.

https://doi.org/10.1182/blood.V120.21.188.188

Published: 2012

Journal Articles

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Blood (2012) 120 (21): 775.

https://doi.org/10.1182/blood.V120.21.775.775

Published: 2012

NARROW

Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

The Role of Tetraspanin CD37 in B-Cell Malignancy

Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only